Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL6800533 | 0.92 | PRMT5 (0.35) | PRMT5WDR77ABCB1CTSSATM | |
| Lithium Ion SCHEMBL6794513 | 0.91 | PRMT5 (0.35) | PRMT5WDR77ABCB1CTSSATM | |
| SCHEMBL6787013 | 0.91 | PRMT5 (0.38) | PRMT5WDR77USP2ABCB1CTSS | |
| Lithium Ion SCHEMBL6793854 | 0.86 | CTSS (0.37) | PRMT5WDR77CTSS | |
| Lithium Ion SCHEMBL6792086 | 0.84 | PRMT5 (0.37) | PRMT5WDR77CTSS | |
| Lithium Ion SCHEMBL6792451 | 0.83 | AGER (0.35) | — | |
| Lithium Ion SCHEMBL6793578 | 0.82 | CARM1 (0.36) | PRMT5WDR77 | |
| SCHEMBL6800539 | 0.82 | PRMT5 (0.36) | PRMT5WDR77ABCB1CTSSPLK1 | |
| SCHEMBL6794518 | 0.81 | PLK1 (0.36) | PRMT5WDR77ABCB1CTSSPLK1 | |
| Hydrochloric Acid SCHEMBL6794118 | 0.80 | CTSS (0.38) | PRMT5WDR77CTSSLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | PRMT5 1416/4885WDR77 2717/4885USP2 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.